Ibrutinib Plus CIT for R/R Mature B-NHL in Children (SPARKLE Trial): Initial Safety, Pharmacokinetics, and Efficacy

Authors

G A Amos Burke
Auke Beishuizen
Deepa Bhojwani
Birgit Burkhardt
Véronique Minard-Colin
Robin E. Norris
Edita Kabickova
F Guclu Pinarli
Nurdan Tacyildiz
Angela Howes
Jan de Jong
Grace Liu
Kerri Nottage
Mariya Salman
Xavier Woot de Trixhe
Mitchell Cairo, New York Medical CollegeFollow

DOI

10.1038/s41375-020-0749-5

Journal Title

Leukemia

First Page

2271

Last Page

2275

Document Type

Article

Publication Date

8-2020

Department

Pediatrics

Second Department

Health Behavior and Community Health

Keywords

Adolescent, Child, Child, Preschool, Combined Modality Therapy, Female, Humans, Immunotherapy, Lymphoma, B-Cell, Male, Pyrazoles, Pyrimidines

Disciplines

Medicine and Health Sciences

Recommended Citation

Burke, G. A., Beishuizen, A., Bhojwani, D., Burkhardt, B., Minard-Colin, V., Norris, R. E., Kabickova, E., Pinarli, F. G., Tacyildiz, N., Howes, A., de Jong, J., Liu, G., Nottage, K., Salman, M., de Trixhe, X. W., & Cairo, M. (2020). Ibrutinib Plus CIT for R/R Mature B-NHL in Children (SPARKLE Trial): Initial Safety, Pharmacokinetics, and Efficacy. Leukemia, 34 (8), 2271-2275. https://doi.org/10.1038/s41375-020-0749-5